Share This Page
Drugs in ATC Class M04AB
✉ Email this page to a colleague
Drugs in ATC Class: M04AB - Preparations increasing uric acid excretion
ATC Class M04AB (Preparations Increasing Uric Acid Excretion): Market Dynamics and Patent Landscape
What is the M04AB market, and how is it segmented?
ATC class M04AB is defined as “preparations increasing uric acid excretion.” The market is driven by two sub-mechanism groups:
- Uricosuric monotherapies (historically: probenecid; legacy markets in some regions)
- Urate transport modulation via active uricosurics (modern “target” competitive set is primarily probenecid in regulatory terms; many newer candidates are assigned to different ATC codes depending on label, salt forms, and jurisdictional ATC mapping)
In practice, the commercial “shape” is controlled by:
- Core gout population (urate lowering plus flare management and adherence)
- Formulary positioning against xanthine oxidase inhibitors (M04AA: febuxostat/allopurinol) that dominate first-line or guideline-based starting choices in many markets
- Residual use of uricosurics after inadequate control or intolerance to xanthine oxidase inhibitors
- Substitution economics where payers steer to generics (especially for allopurinol/febuxostat where available) while uricosurics face lower penetration due to tolerability constraints (GI effects, nephrolithiasis risk, and urinalysis/monitoring in some protocols)
Commercial implication: M04AB behaves as a second-line or add-on/step-up segment rather than a primary market.
What are the competitive dynamics inside M04AB?
Pricing power and generic pressure
- If the principal marketed uricosuric is generic in a given geography, pricing power compresses quickly.
- Formularies often treat uricosurics as cost-tiered options, with payer criteria tied to documented hyperuricemia control failure on xanthine oxidase inhibitors or documented intolerance.
Patient selection dynamics
Uricosuric use is constrained by practical clinical requirements:
- Baseline and ongoing assessment of renal function
- Risk management for urinary stone disease (hydration, monitoring)
- Use-case alignment with patients where lowering serum urate via renal excretion is considered clinically appropriate
Switching and adherence
Compared with once-daily xanthine oxidase inhibitors, uricosurics frequently face:
- More complex dosing schedules in certain labeled regimens
- Higher monitoring burden These features reduce “default switching” from the most established urate-lowering therapies.
What is the patent landscape for M04AB urate-excretion preparations?
A robust patent landscape for M04AB exists primarily through:
- Old foundational compounds (largely expired in major jurisdictions for the canonical uricosuric)
- Formulation and dosing regimen patents (extended release, improved tolerability, fixed-dose combinations)
- Use patents (gout subpopulations, stone-risk mitigation dosing schedules, renal impairment stratification)
- Salt form and polymorph strategy (where applicable)
For the canonical uricosuric associated with this class, the patent landscape is dominated by:
- Early-20th-century compound IP, now expired
- Later improvements that cluster around formulation and label expansion rather than new chemical entity protection
Net effect: M04AB is typically a low-NCE-protection landscape with high genericization risk, and most remaining enforceable value (where present) comes from narrow formulation or method-of-use claims.
Where do ATC M04AB drugs sit versus other urate-lowering classes in patent value?
Patent value in gout is materially higher in other urate-lowering classes:
- XO inhibitors (M04AA) have had multiple waves of incremental protection across jurisdictions through reformulations and different active substances and combinations.
- Newer gout agents that drive patent-intensive pipelines often classify outside M04AB due to ATC assignment (for example, uricase or novel mechanisms assigned to different ATC subclasses).
M04AB therefore tends to lag on pipeline novelty relative to other gout mechanisms. Investors and R&D planners usually treat it as a defensive generics and line-extension market unless a company owns a modern, enforceable formulation or use patent.
What is the actionable patent reality for M04AB products?
1) Primary compound patents
- The canonical uricosuric within M04AB has aging and expiry characteristics consistent with older chemical entities.
- As a result, the market experiences generic erosion in key geographies.
2) Secondary IP that can still matter
Even where compound patents are expired, enforcement can still exist through:
- Extended-release or improved-release formulations
- Improved dosing regimens aimed at lowering GI toxicity or improving compliance
- Compositions with co-medication logic (for example, hydration guidance is clinical; true composition combinations require explicit formulation IP)
- Polymorph or solid-state form exclusivity (where successfully claimed and pursued)
3) Litigation and regulatory challenges
In low-NCE landscapes, patent value is concentrated in:
- Method-of-use claims that are tied to clinical protocols
- Formulation claims that can be designed around if generic manufacturers take different release profiles or salts
Actionable interpretation: For M04AB, diligence should prioritize expiry timing and claim scope for formulation and method patents, not broad compound claims.
What are the key market drivers that affect volumes in M04AB?
Guideline sequencing
Across major markets, clinicians commonly start with xanthine oxidase inhibitors for many patients. That sequencing reduces first-order demand for uricosurics.
Renal function and stone risk management
Uricosurics face patient selection and monitoring:
- Decreased use when renal impairment is present
- Risk mitigation protocols increase friction and can push prescribers away from uricosuric monotherapy
Adherence and outcomes
Long-term serum urate control drives:
- Dose adjustments and titration
- Continued therapy even after flare stabilization
In M04AB, the adherence challenge can reduce persistence compared with fixed once-daily schedules typical in xanthine oxidase inhibitor regimens.
Where does the market opportunity exist, despite low NCE novelty?
Most opportunities sit in:
- Narrow line extensions: improved tolerability formulations, simplified dosing schedules, or better patient targeting
- Geographic gaps: jurisdictions where generics lag or where specific labeled formulations persist
- Add-on niches: patients inadequately controlled on or intolerant to other urate-lowering options
From a portfolio perspective, M04AB is best treated as:
- Defensive revenue for companies with formulation IP still protected
- Selective growth for developers with differentiated solid-state, release technology, or clinically meaningful dosing regimen patents
What diligence items determine whether M04AB patents are enforceable value?
A disciplined IP review for M04AB should focus on:
- Jurisdiction-by-jurisdiction claim validity (not just filing dates)
- Grant and claim construction status for method-of-use claims
- Formulation specificity (solid-state form, release kinetics, excipient framework)
- Design-around plausibility for salts, polymorphs, and release mechanics
- Regulatory exclusivity interaction (if any) with patent term calculations
Key Takeaways
- M04AB is a urate-excretion segment with constrained first-line demand, shaped by guideline sequencing and clinical monitoring requirements.
- Patent value is concentrated in secondary IP (formulation and method-of-use), while primary compound protection is typically expired for the canonical uricosuric class member.
- Market upside is niche and execution-driven: differentiated formulation, protected dosing regimens, or geographic/label-specific persistence.
- For R&D and investment screens, the highest signal comes from claim scope and enforceability of formulation/use patents, not broad compound-era patents.
- Competitive dynamics favor generic substitution unless a developer owns modern, enforceable, narrow IP that is difficult to design around.
FAQs
-
Is M04AB the same as all uricosuric products globally?
No. M04AB maps to “preparations increasing uric acid excretion” and can exclude some modern urate-lowering agents that are classified elsewhere by ATC assignment. -
What typically protects revenue in M04AB when compound patents expire?
Formulation and method-of-use patents, including improved release profiles, solid-state forms, and tightly defined clinical use claims. -
Why does M04AB usually underperform relative to XO inhibitors?
Clinical sequencing, tolerability constraints, and monitoring requirements reduce default prescribing compared with xanthine oxidase inhibitors. -
Where can a new entrant win in M04AB?
Narrow niches where enforceable formulation differences or use-regimen protections exist, or where generics are delayed and label persistence supports market uptake. -
What is the main commercial risk for M04AB innovators?
Rapid genericization and design-around of narrow formulation claims unless the IP portfolio is robust across jurisdictions.
References
- WHO Collaborating Centre for Drug Statistics Methodology. ATC classification system: M04AB. https://www.whocc.no/atc/structure/ (accessed 2026-04-25).
More… ↓
